You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

339 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
    dexamethasone
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Aug 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Jul 2025
Regimen
Intent: Adjuvant, Curative, Palliative
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Leukemia - Chronic Lymphocytic (CLL), 
Leukemia - Hairy Cell, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Curative, Palliative
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Jul 2025
Guidelines and Advice
Updated
Aug 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Funding:
New Drug Funding Program
    Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Exceptional Access Program
    Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia
Sep 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Curative, Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Primary Advanced or Recurrent Endometrial Carcinoma
Sep 2025
Drug
Other Name(s): Vitrakvi®
Sep 2025

Pages